



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Charlotte Moira Norfor Allerton

SERIAL NO.: 10/727,168

FILED: December 2, 2003

TITLE: Morpholine Dopamine Agonists

GROUP ART UNIT: 1626

EXAMINER: Kamal A. Saeed

DATE: June 15, 2007

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97-1.98

Commissioner for Patents Alexandria, VA 22313

Sir:

This Supplemental Information Disclosure Statement is filed pursuant to 37 CFR 1.97-1.98 and MPEP §609. The present Information Disclosure Statement supplements the Information Disclosure Statement previously submitted. Any fee required by 37 CFR 1.97-1.98 should be charged to Deposit Account No. 161445.

This newly cited document is as pertinent as the documents previously cited in this prosecution.

Respectfully submitted,

Philip B. Polster II Attorney for Applicants Registration No. 43,864

Tel: 314-274-9094

Pharmacia Corporation of Pfizer Inc Corporate Patent Department P.O. Box 1027 Chesterfield, MO 63306

<b>17</b>		5114411		
FORM PTO-144 O.S. DEPARTMENT O COMMERCE, PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: PC25420A	APPLICATION NO.: 10/727,168		
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	INVENTOR: Charlotte Moira Norfor Allerton			
(Use several sheets if necessary)	Filed: 12/2/2003	Group 1626		

## **U.S. PATENT DOCUMENTS**

Examiner Initi							Filing Date If Appropr
		Document Numbe	Date	Name	Class	Subclass	
	A1	5,258,513	11/2/93	Van Keulen	C07D	251/08	
	A2	5,348,956	9/20/94	Van Keulen	A61K	31/535	

## FOREIGN PATENT DOCUMENTS

Examiner							Translatio	on
Initial		Document Number	Date	Country	Class	Subclass	Y	No
	B1	WO92/18489	10/29/1992	PCT	C07D	265/30		
	B2	GB851311A	10/12/60	GB	C07D			
	B3	SU1154907 A1	9/20/96	SU	C07D	295/12		
	B4	RU2095353 C1	10/11/97	RU	C07D	. 251/12		
								<del>-</del>
	+							
	+-					* *		
	- 1	i	l	i l			l	

EXAMINER	DATE CONSIDERED				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Dr.					
line through citation if not in conformance and not	considered. Include copy of this form with next				

communication to applicant.